Corbus Pharmaceuticals Holdings, Inc.
CRBP
$10.09
$0.010.10%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 31.18M | 19.82M | 18.41M | 20.86M | 15.19M |
| Gross Profit | -31.18M | -19.82M | -18.41M | -20.86M | -15.19M |
| SG&A Expenses | 5.02M | 4.49M | 3.56M | 3.56M | 3.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.19M | 24.30M | 21.97M | 24.42M | 19.15M |
| Operating Income | -36.19M | -24.30M | -21.97M | -24.42M | -19.15M |
| Income Before Tax | -35.04M | -22.97M | -20.56M | -23.34M | -17.66M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -35.04M | -22.97M | -20.56M | -23.34M | -17.66M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.04M | -22.97M | -20.56M | -23.34M | -17.66M |
| EBIT | -36.19M | -24.30M | -21.97M | -24.42M | -19.15M |
| EBITDA | -36.14M | -24.26M | -21.92M | -24.37M | -19.10M |
| EPS Basic | -1.81 | -1.23 | -1.25 | -1.90 | -1.44 |
| Normalized Basic EPS | -1.13 | -0.77 | -0.82 | -1.19 | -0.90 |
| EPS Diluted | -1.81 | -1.23 | -1.25 | -1.90 | -1.44 |
| Normalized Diluted EPS | -1.13 | -0.77 | -0.82 | -1.19 | -0.90 |
| Average Basic Shares Outstanding | 19.41M | 18.71M | 16.48M | 12.31M | 12.24M |
| Average Diluted Shares Outstanding | 19.41M | 18.71M | 16.48M | 12.31M | 12.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |